Essential Pharma & Clinigen Expand JAPAC Partnership to Ensure Patient Access

Essential Pharma, a global specialty pharmaceutical organization dedicated to providing patients with access to low volume, clinically distinct niche pharmaceutical products in vital therapeutic fields, and Clinigen, the worldwide specialty pharmaceutical services organization, have revealed an enhancement of their JAPAC partnership, designed to promote ongoing patient access to four therapies in Japan and Korea while fortifying their joint market presence in the area.

This enlarged partnership includes multiple new market authorization transfers and exclusive distribution contracts. Following their 2024 pact for IOPIDINE® (apraclonidine) in Korea, Essential Pharma and Clinigen now broaden this to Japan. New contracts create market authorization transfer and exclusive distribution for HALDOL® (haloperidol) and REMINYL® (galantamine) oral capsules in Korea, as well as for HALOMONTH® (haloperidol decanoate) in Japan.

IOPIDINE 5mg/ml serves as a short-term supplementary treatment for chronic glaucoma patients who are on the highest tolerable medical therapy to manage or reduce intraocular pressure.

HALDOL and HALOMONTH are antipsychotic medications that contain haloperidol and are utilized in treating schizophrenia and various psychiatric disorders, including schizoaffective disorder. Haloperidol is listed in the World Health Organization's 2023 List of Essential Medicines1. REMINYL, a cholinesterase inhibitor, is a CNS medication utilized to manage symptomatic mild to moderate Alzheimer-type dementia.